By Nana O 
Scientists at the University of Cambridge have achieved a groundbreaking feat, creating sophisticated lab-grown brain and spinal cord systems that meticulously replicate the intricate pathways of movement signals within the human nervous system. This remarkable innovation has led to a paradigm-shifting discovery: nerve damage, long considered irreversible, may indeed be susceptible to repair under specific developmental conditions. The research, published in the prestigious journal Cell Reports, utilizes human organoids to unlock fundamental insights into neural regeneration, potentially paving the way for novel therapeutic interventions for debilitating neurological conditions.
The Intricacies of Neural Communication and the Challenge of Regeneration
The journey from embryonic development to a fully formed infant is characterized by the establishment of complex neural networks. Neurons, the fundamental building blocks of the nervous system, form intricate communication lines between the brain and the spinal cord. These signals, responsible for orchestrating everything from voluntary muscle movements to involuntary bodily functions, are transmitted along axons. These elongated nerve fibers act as vital conduits, enabling neurons to transmit electrochemical messages and control the body’s actions.
However, a critical challenge emerges as the central nervous system matures. The remarkable regenerative capacity observed in developing neurons significantly diminishes in adulthood. This decline in axon regrowth ability is a primary reason why injuries to the brain or spinal cord often result in permanent disabilities, such as paralysis, loss of sensation, or impaired motor function. This regenerative failure is also implicated in the progression of devastating neurological diseases, including motor neurone disease (ALS) and multiple sclerosis (MS), where neuronal damage leads to progressive functional decline. For decades, the scientific community has grappled with understanding the precise mechanisms behind this loss of regenerative potential, seeking to identify ways to circumvent or reverse it.
Pioneering Mini Human Brain and Spinal Cord Models
Building upon their previous success in creating miniature human brain models in 2021, Dr. András Lakatos and his team at the University of Cambridge have advanced their research by constructing a more comprehensive, connected brain and spinal cord system in vitro. These earlier "brain organoids," approximately pea-sized and derived from patient stem cells, successfully mimicked aspects of the cerebral cortex. They proved instrumental in studying the molecular underpinnings of motor neurone disease and exploring potential preventative strategies.
The latest study takes this a significant step further by linking these brain organoids with spinal cord organoids. Recognizing the distinct yet interconnected nature of these structures in vivo, the researchers maintained the brain and spinal cord organoids in separate compartments within the laboratory. Through meticulous observation, they witnessed axons extending from the brain tissue across the physical gap, establishing functional connections with the spinal cord tissue. This artificial neural circuit proved sufficiently robust to elicit contractions in small clusters of muscle cells, demonstrating the viability and functionality of the engineered system.
Unveiling the Developmental Timeline of Nerve Regrowth Decline
A crucial aspect of this research involved observing these miniature neural systems over an extended period, exceeding one year in the lab. This prolonged observation window allowed the scientists to map the changes in regenerative capacity as the organoids matured. Their findings revealed a critical developmental window: up until approximately day 150 of development – a period roughly analogous to the middle trimester of human gestation – damaged axons within these organoids retained the ability to regrow. Beyond this point, however, the neurons exhibited a precipitous decline in their regenerative potential.
George Gibbons, a lead author of the study from the Department of Clinical Neurosciences at the University of Cambridge, elaborated on this pivotal observation. "Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow," Gibbons stated. "In other words, poor regeneration is built into human neurons as they mature in the central nervous system." This suggests that the loss of regenerative ability is not an external imposition but rather an intrinsic developmental process.
Decoding the Genetic Switch for Axon Growth
To unravel the underlying molecular mechanisms responsible for this developmental decline in regeneration, the research team delved into the gene activity of neurons connecting the brain and spinal cord. Their comprehensive analysis identified a complex network of genes that appears to function as a biological "switch." This network plays a pivotal role in curtailing axon growth as neurons mature and establish synaptic connections, the critical junctions for neural communication.
The implications of this discovery are profound. By understanding this genetic regulatory network, scientists gain a clearer picture of why regeneration falters with age. More excitingly, the researchers demonstrated that by selectively blocking key regulators within this network, they could effectively "reactivate" the neurons’ ability to grow axons. This intervention restored a degree of regenerative capacity to mature neurons, a feat previously thought to be largely impossible.
A Promising Avenue: Existing Drug Shows Potential for Nerve Regeneration
In a significant translational step, the Cambridge team then explored a database of existing drug compounds to identify molecules that could modulate this newly identified gene network. Among the promising candidates was lynestrenol, a synthetic progestogen hormone drug. Lynestrenol is already approved and widely used for specific menstrual disorders and as a contraceptive.
The researchers investigated the efficacy of lynestrenol by testing it on damaged neurons in their organoid model. The results were highly encouraging, with the drug demonstrating a significant improvement in axon regrowth. This finding suggests that an existing, clinically approved medication could potentially be repurposed to promote nerve repair.
While acknowledging that scar tissue and inflammation are significant impediments to nerve repair in clinical settings, the study emphasizes the critical importance of understanding neuron-specific biological mechanisms that limit regeneration. Previous research has indicated that younger neurons can navigate and grow through environments that typically hinder repair at injury sites. This new work provides a crucial piece of the puzzle by identifying an intrinsic factor within the neurons themselves that limits this capacity.
Senior author Dr. András Lakatos, who led the study, underscored the significance of their findings. "When the brain and spinal cord are damaged, the nerve fibers that carry movement signals from the brain to the spinal cord rarely grow back. That’s why paralysis is usually permanent. But we didn’t know exactly when the ability of axons to regenerate becomes limited," Dr. Lakatos explained. "Our model provides a good indication that this block happens during development, and it can still be reversed after this point."
He further elaborated on the therapeutic potential: "Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable."
The Growing Importance of Human Organoids in Biomedical Research
The development and application of organoid technology are increasingly recognized as invaluable tools for advancing our understanding of human biology and disease. While animal models, such as mice and rats, have historically played a crucial role in scientific research, inherent biological differences can limit their accuracy in reflecting the complexities of the human nervous system.
Human stem cell-derived organoids, such as those developed by the Cambridge team, offer a more precise recapitulation of human biology. This allows researchers to bridge the gap between findings in animal studies and their potential relevance to real-world patient outcomes. This advancement is particularly critical in neurobiology, where interspecies differences in neural circuitry and regenerative mechanisms can lead to misleading conclusions.
Dr. Lakatos highlighted the value of these models: "Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons. Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research." This ethical consideration aligns with the broader scientific push towards reducing reliance on animal testing, a growing priority in the biomedical community.
The University of Cambridge is at the forefront of utilizing organoid technology for a diverse array of medical studies. Beyond neuroregeneration, researchers are employing organoids to investigate liver repair, understand the complexities of Crohn’s disease in pediatric patients, and explore the earliest, most sensitive stages of human pregnancy. This broad application underscores the versatility and transformative potential of organoid technology across multiple medical disciplines.
This groundbreaking research was generously supported by funding from UK Research and Innovation (UKRI) through the Medical Research Council and Spinal Research, organizations dedicated to advancing medical science and improving the lives of individuals affected by spinal cord injuries. The collaborative effort and financial backing have been instrumental in bringing this promising discovery to light.
Future Directions and Broader Implications
The implications of this research extend far beyond the immediate discovery of lynestrenol’s potential. It fundamentally shifts our understanding of nerve damage, moving from a narrative of inevitability to one of potential reversibility. The ability to manipulate the intrinsic regenerative capacity of human neurons opens up exciting avenues for therapeutic development.
Future research will undoubtedly focus on several key areas. Firstly, detailed investigations into how lynestrenol and similar compounds influence the identified gene network in more complex in vivo models will be crucial. Secondly, the challenge of ensuring that regenerated axons form appropriate and functional connections within the central nervous system needs to be addressed. This involves not only encouraging axon growth but also guiding it to the correct targets to restore lost function. Thirdly, researchers will need to investigate the safety and efficacy of such interventions in preclinical animal models before any human trials can be considered.
The broader impact of this work could be transformative for millions of individuals worldwide affected by spinal cord injuries, stroke, neurodegenerative diseases, and other conditions that involve nerve damage. While the journey from laboratory discovery to clinical application is often long and complex, this Cambridge breakthrough offers a tangible beacon of hope, suggesting that conditions once considered untreatable may, in the future, become amenable to therapeutic intervention. The development of these advanced organoid models represents a significant leap forward in our ability to study, understand, and ultimately, repair the human nervous system.
